CureVac Netherlands B.V. is part of CureVac AG: a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA) with the main goal to bring multiple best-in-class mRNA drugs to market. As Antigen Discovery and Validation Center, CureVac Netherlands focuses on developing innovative cancer immunotherapies. We will focus on the design and clinical validation of a first off-the-shelf vaccine targeting a number of shared cancer antigens. In parallel, the antigen discovery technology will be improved and expanded with the goal to develop a platform that enables the detection of all possible antigens expressed by cancer cells. Such platform will form the basis for off-the-shelf and personalized vaccine design for many different cancer types.